68.19
Haemonetics Corp stock is traded at $68.19, with a volume of 782.44K.
It is up +0.26% in the last 24 hours and up +11.73% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$68.01
Open:
$67.75
24h Volume:
782.44K
Relative Volume:
0.88
Market Cap:
$3.21B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
28.29
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
+6.80%
1M Performance:
+11.73%
6M Performance:
-22.00%
1Y Performance:
-26.36%
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HAE
Haemonetics Corp
|
68.19 | 3.21B | 1.36B | 123.81M | 20.35M | 2.41 |
![]()
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-06-24 | Initiated | JP Morgan | Overweight |
Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-13-24 | Initiated | CL King | Buy |
Sep-11-24 | Initiated | BofA Securities | Neutral |
Sep-10-24 | Initiated | BTIG Research | Buy |
Jun-12-24 | Upgrade | Needham | Hold → Buy |
Oct-13-22 | Initiated | Mizuho | Buy |
Jan-27-22 | Downgrade | Needham | Buy → Hold |
Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
Aug-17-21 | Resumed | Raymond James | Outperform |
Jun-17-21 | Initiated | Citigroup | Buy |
May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
Jan-10-20 | Initiated | Needham | Buy |
Aug-07-19 | Reiterated | Barrington Research | Outperform |
May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
May-08-19 | Reiterated | Barrington Research | Outperform |
Aug-09-18 | Reiterated | Barrington Research | Outperform |
Feb-07-18 | Reiterated | Barrington Research | Outperform |
Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-08-17 | Reiterated | Barrington Research | Outperform |
Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
Nov-07-16 | Reiterated | The Benchmark Company | Hold |
Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
Aug-02-16 | Reiterated | Jefferies | Buy |
Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings - Yahoo Finance
Raymond James Reiterates Strong Buy on Haemonetics (HAE) with Lo - GuruFocus
Raymond James Reiterates Strong Buy on Haemonetics (HAE) with Lowered Price Target | HAE Stock News - GuruFocus
Raymond James Adjusts Haemonetics (HAE) Price Target to $105, Ma - GuruFocus
Haemonetics Corp (HAE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo
Haemonetics (HAE) Rating Maintained, Price Target Lowered to $84 | HAE Stock News - GuruFocus
Haemonetics: Fiscal Q4 Earnings Snapshot - MySA
Transcript : Haemonetics Corporation, Q4 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Haemonetics Q4 2025 beats EPS forecast, stock rises - Investing.com
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Haemonetics' Fiscal Q4 Adjusted Earnings Rise, Revenue Falls; Fiscal 2026 Outlook Issued - marketscreener.com
Haemonetics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Haemonetics earnings beat by $0.02, revenue topped estimates - Investing.com
Haemonetics (NYSE:HAE) Surprises With Q1 Sales - Yahoo Finance
Haemonetics Corp Surpasses Q4 Expectations with EPS of $1.17 and Revenue of $331 Million - GuruFocus
Haemonetics (HAE) Surpasses Q4 Revenue Expectations | HAE Stock News - GuruFocus
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website - Quantisnow
Haemonetics Corporation announces an Equity Buyback for $500 million worth of its shares. - marketscreener.com
Earnings To Watch: Haemonetics Corp (HAE) Reports Q4 2025 Result - Yahoo Finance
Haemonetics (HAE) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Haemonetics Sues Terumo Over Plasma Tech Patents - Law360
Haemonetics (NYSE:HAE) Upgraded to “Buy” at StockNews.com - Defense World
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday - Defense World
BofA Securities’s latest rating for HAE stock - knoxdaily.com
Envestnet Asset Management Inc. Buys 4,217 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Taking on analysts’ expectations and winning: Haemonetics Corp (HAE) - Sete News
How Do Investors Really Feel About Haemonetics?Haemonetics (NYSE:HAE) - Benzinga
Bank of Montreal Can Sells 12,518,398 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Cerity Partners LLC Decreases Stock Position in Haemonetics Co. (NYSE:HAE) - Defense World
Haemonetics Co. (NYSE:HAE) Shares Sold by Legal & General Group Plc - The AM Reporter
Reviewing Haemonetics (NYSE:HAE) and Apyx Medical (NASDAQ:APYX) - Defense World
Is Haemonetics Corporation (HAE) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - Insider Monkey
Patient Blood Management Market is Set to Experience - openPR.com
BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know - Yahoo Finance
Haemonetics stock touches 52-week low at $58.24 amid challenges By Investing.com - Investing.com South Africa
Haemonetics stock touches 52-week low at $58.24 amid challenges - Investing.com Australia
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
Vanguard Group Inc. Purchases 10,119 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
Prudential Financial Inc. Decreases Stock Holdings in Haemonetics Co. (NYSE:HAE) - Defense World
HighTower Advisors LLC Buys 244 Shares of Haemonetics Co. (NYSE:HAE) - Defense World
3 Reasons to Avoid HAE and 1 Stock to Buy Instead - Yahoo Finance
Haemonetics Corp. (HAE): Among the 10 Pro-Life Companies to Invest In Now? - Insider Monkey
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 - Yahoo Finance
Haemonetics Co. (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
10 Pro-Life Companies to Invest In Now - Insider Monkey
A Note On Haemonetics Corporation's (NYSE:HAE) ROE and Debt To Equity - Yahoo Finance
Fractional Flow Reserve Market Set for 11.27% CAGR Growth by 2031 - openPR
Haemonetics (NYSE:HAE) Given New $104.00 Price Target at Needham & Company LLC - Defense World
Is it Apt to Retain HAE Stock in Your Portfolio for Now? - Nasdaq
Demystifying Haemonetics: Insights From 5 Analyst Reviews - Nasdaq
Needham Trims Price Target on Haemonetics to $104 From $108, Keeps Buy Rating -March 18, 2025 at 06:53 am EDT - MarketScreener
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):